40 results on '"Grünig, Ekkehard"'
Search Results
2. Seralutinib in adults with pulmonary arterial hypertension (TORREY): a randomised, double-blind, placebo-controlled phase 2 trial
3. Effect of Eccentric Cycling on Oxygen Uptake and Hemodynamics in Patients With Pulmonary Vascular Disease: A Randomized Controlled Crossover Trial
4. Submaximal, Low-Dose Eccentric vs Traditional Cycling Exercise: Reduced Oxygen Uptake and Pulmonary Artery Pressure Assessed by Echocardiography in Healthy Middle-aged Adults. A Randomized Controlled, Crossover Trial
5. Randomized Trial of Macitentan/Tadalafil Single-Tablet Combination Therapy for Pulmonary Arterial Hypertension
6. Defining the clinical validity of genes reported to cause pulmonary arterial hypertension
7. Risk stratification and response to therapy in patients with pulmonary arterial hypertension and comorbidities: A COMPERA analysis
8. Genetics of High-Altitude Pulmonary Edema
9. Phenotyping of idiopathic pulmonary arterial hypertension: a registry analysis
10. When Pulmonary Hypertension Complicates Heart Failure
11. Three- Versus Two-Drug Therapy for Patients With Newly Diagnosed Pulmonary Arterial Hypertension
12. Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial
13. Riociguat treatment in patients with chronic thromboembolic pulmonary hypertension: Final safety data from the EXPERT registry
14. Riociguat treatment in patients with pulmonary arterial hypertension: Final safety data from the EXPERT registry
15. Idiopathic pulmonary arterial hypertension phenotypes determined by cluster analysis from the COMPERA registry
16. When Pulmonary Hypertension Complicates Heart Failure
17. Long-term safety and outcome of intravenous treprostinil via an implanted pump in pulmonary hypertension
18. REVEAL risk score in patients with chronic thromboembolic pulmonary hypertension receiving riociguat
19. The Right Heart International Network (RIGHT-NET): Rationale, Objectives, Methodology, and Clinical Implications
20. Exercise Training and Rehabilitation in Pulmonary Hypertension
21. Simultaneous quantification of endothelin receptor antagonists and phosphodiesterase 5 inhibitors currently used in pulmonary arterial hypertension
22. Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial
23. BMPR2 mutations and survival in pulmonary arterial hypertension: an individual participant data meta-analysis
24. Change of right heart size and function by long-term therapy with riociguat in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
25. Genetics and Genomics of Pulmonary Arterial Hypertension
26. Assessment of Pulmonary Arterial Pressure During Exercise in Collagen Vascular Disease: Echocardiography vs Right-Sided Heart Catheterization
27. Right Ventricular Systolic Pressure Response During Exercise in Adolescents Born With Atrial or Ventricular Septal Defect
28. Quantitative 3D pulmonary MR-perfusion in patients with pulmonary arterial hypertension: Correlation with invasive pressure measurements
29. ORAL TREPROSTINIL AS PART OF A TRIPLE-THERAPY REGIMEN FOR PULMONARY ARTERIAL HYPERTENSION: ANALYSIS FROM THE FREEDOM-EV OPEN-LABEL EXTENSION
30. Contribution of stress echocardiography to clinical decision making in unselected ambulatory patients with known or suspected coronary artery disease
31. RETRACTED: Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study
32. Cellular pathophysiology and therapy of pulmonary hypertension
33. TREATMENT BENEFITS ASSOCIATED WITH OPEN LABEL ORAL TREPROSTINIL AFTER CLINICAL WORSENING IN THE PHASE 3 FREEDOM-EV STUDY FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION
34. Adult patients with congenital heart disease and pulmonary arterial hypertension: First open prospective multicenter study of bosentan therapy
35. Long-term Riociguat Treatment in PAH Patients in WHO Functional Class (FC) I/II Versus FC III/IV at Baseline: Results From the 12-Week Phase III PATENT-1 Study and PATENT-2 Open-Label Extension
36. Riociguat for the Treatment of Pulmonary Arterial Hypertension (PAH): 1-Year Results from the PATENT-2 Long-term Extension Study
37. An Evidence-Based Screening Algorithm for Pulmonary Arterial Hypertension in Systemic Sclerosis: The DETECT Study
38. Imatinib Improves Exercise Capacity and Hemodynamics at 24 Weeks as Add-on Therapy in Symptomatic Pulmonary Arterial Hypertension Patients: The IMPRES Study
39. SCREENING FOR PULMONARY ARTERIAL HYPERTENSION WITH EXERCISE-STRESS-ECHOCARDIOGRAPHY AND CARDIOPULMONARY EXERCISE TESTING
40. ACUTE HEMODYNAMIC EFFECT OF SILDENAFIL IN COMPARISON WITH INHALED NITRIC OXIDE IN PATIENTS RECEIVING BOSENTAN THERAPY FOR PULMONARY ARTERIAL HYPERTENSION
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.